Vext ScienceVEXTF 71 Quick Ratio is 0.31 as of Mar. 2026, which is 87% below its 10-year median of 2.46. GuruFocus rates VEXTF with a GF Score™ of 71/100 and a GF Value™ of $1.08 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 996 Drug Manufacturers companies, Vext Science ranks worse than 93.17% on this metric.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Vext Science's quick ratio for the quarter that ended in Mar. 2026 was 0.31.
Vext Science has a quick ratio of 0.31. It indicates that the company cannot currently fully pay back its current liabilities.
The historical rank and industry rank for Vext Science's Quick Ratio or its related term are showing as below:
VEXTF'
s Quick Ratio Range Over the Past 10 Years
Min: 0.31 Med: 2.46 Max: 11.58
Current: 0.31
During the past 9 years, Vext Science's highest Quick Ratio was 11.58. The lowest was 0.31. And the median was 2.46.
VEXTF's Quick Ratio is ranked worse than 93.17% of 996
companies
in the Drug Manufacturers industry
Industry Median: 1.45
vs VEXTF: 0.31
Vext Science (OTCPK:VEXTF) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Vext Science Quick Ratio Related Terms
Vext Science Quick Ratio Historical Data
* Premium members only.
The historical data trend for Vext Science's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Vext Science's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vext Science Quick Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vext Science's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Vext Science's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Vext Science's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vext Science (VEXTF) has a Quick Ratio of 0.31 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Vext Science and its competitors. This is 87% below median its historical median of 2.46. Over the past decade, Vext Science's Quick Ratio has ranged from 0.31 to 11.58. According to the industry distribution chart, Vext Science ranks #928 out of 996 companies in the Drug Manufacturers industry, placing it in the top 93.2%.
Is Vext Science's Quick Ratio too high?
Vext Science's current Quick Ratio of 0.31 is 87% below median its 10-year median of 2.46. Over the past 10 years, this metric has ranged from a low of 0.31 to a high of 11.58. The Drug Manufacturers industry median Quick Ratio is 1.45. Vext Science's value of 0.31 is 78.6% below this industry median. Based on the distribution chart, Vext Science ranks #928 out of 996 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Vext Science has a GF Score™ of 71/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Vext Science's Quick Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Vext Science ranks #928 out of 996 companies for Quick Ratio. This places Vext Science in the lower half of its industry. The industry median Quick Ratio is 1.45. Vext Science's value of 0.31 is 78.6% below this benchmark. Historically, Vext Science's own Quick Ratio has ranged from 0.31 to 11.58 over the past decade. While the company's 10-year median is 2.46 vs. the industry median of 1.45, Vext Science has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Drug Manufacturers company?
The median Quick Ratio among Drug Manufacturers companies is 1.45, based on 996 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vext Science's current Quick Ratio of 0.31 is 78.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Vext Science and its competitors. For the Drug Manufacturers industry, the median Quick Ratio is 1.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vext Science's current Quick Ratio is 0.31, which is 87% below median its own 10-year median of 2.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vext Science stock overvalued right now?
Based on GuruFocus' analysis, Vext Science (VEXTF) is currently considered Possible Value Trap. The stock's GF Value™ is $1.08, compared to a current price of $0.16 — trading 84.9% below its estimated fair value. The current Quick Ratio is 0.31, which is 87% below median its 10-year median of 2.46 and 78.6% below the Drug Manufacturers industry median of 1.45. Vext Science's overall GF Score™ is 71/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Vext Science (VEXTF), the current Quick Ratio is 0.31 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vext Science (VEXTF) Overvalued in 2026?
Based on GuruFocus' analysis, Vext Science stock appears to be undervalued.
The current stock price of $0.16 is trading 84.9% below its estimated GF Value™ of $1.08.
GuruFocus considers Vext Science to be Possible Value Trap.
Key valuation signals for VEXTF:
Quick Ratio: 0.31 (87% below median its 10-year median of 2.46)
GF Value™: $1.08 vs. price of $0.16 (84.9% below fair value)
Industry Position: 78.6% below the Drug Manufacturers median (#928 of 996)
No single metric tells the full story. See the VEXTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vext Science Inc engages in the full spectrum of the cannabis product lifecycle, from development and manufacturing to distribution. Its brands include Herbal Wellness, Appalachian Pharm, Revibe, Prism, Vapen, and Firebrand. In Arizona and Ohio, the dispensaries operate under the Herbal Wellness Center brand, while in Ohio the cultivation and manufacturing operations are licensed and branded as Appalachian Pharms Cultivation and Appalachian Pharm Processing. The Company operates through a single operating segment engaged in the cultivation, manufacturing, distribution, and sale of cannabis within the United States. All revenues are generated in the United States.
71GF Score
Get the complete analysis for VEXTF
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VEXTF has been successfully added to your 
